Flavonoid-rich extract of Chromolaena odorata modulate circulating GLP-1 in Wistar rats : computational evaluation of TGR5 involvement
Chromolaena odorata is a major bio-resource in folkloric treatment of diabetes. In the present study, its anti-diabetic component and underlying mechanism were investigated. A library containing 140 phytocompounds previously characterized from C. odorata was generated and docked (Autodock Vina) into homology models of dipeptidyl peptidase (DPP)-4, Takeda-G-protein-receptor-5 (TGR5), glucagon-like peptide 1 (GLP1) receptor, renal sodium dependent glucose transporter (SGLUT)-1/2 and nucleotide-binding oligomerization domain (NOD) proteins 1&2. GLP-1 gene (RT-PCR) modulation and its release (EIA) by C. odorata were confirmed in vivo. From the docking result above, TGR5 was identified as a major target for two key C. odorata flavonoids (5,7-dihydroxy-6-4-dimethoxyflavanone and homoesperetin-7-rutinoside); sodium taurocholate and C. odorata powder included into the diet of the animals both raised the intestinal GLP-1 expression versus control (p < 0.05); When treated with flavonoid-rich extract of C. odorata (CoF) or malvidin, circulating GLP-1 increased by 130.7% in malvidin-treated subjects (0 vs. 45 min). CoF treatment also resulted in 128.5 and 275% increase for 10 and 30 mg/kg b.w., respectively.
CONCLUSIONS: The results of this study support that C. odorata flavonoids may modulate the expression of GLP-1 and its release via TGR5. This finding may underscore its anti-diabetic potency.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
3 Biotech - 8(2018), 2 vom: 01. Feb., Seite 124 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Omotuyi, Olaposi Idowu [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 01.10.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1007/s13205-018-1138-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM281087083 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM281087083 | ||
003 | DE-627 | ||
005 | 20231225030822.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13205-018-1138-x |2 doi | |
028 | 5 | 2 | |a pubmed24n0936.xml |
035 | |a (DE-627)NLM281087083 | ||
035 | |a (NLM)29450114 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Omotuyi, Olaposi Idowu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Flavonoid-rich extract of Chromolaena odorata modulate circulating GLP-1 in Wistar rats |b computational evaluation of TGR5 involvement |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 01.10.2020 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Chromolaena odorata is a major bio-resource in folkloric treatment of diabetes. In the present study, its anti-diabetic component and underlying mechanism were investigated. A library containing 140 phytocompounds previously characterized from C. odorata was generated and docked (Autodock Vina) into homology models of dipeptidyl peptidase (DPP)-4, Takeda-G-protein-receptor-5 (TGR5), glucagon-like peptide 1 (GLP1) receptor, renal sodium dependent glucose transporter (SGLUT)-1/2 and nucleotide-binding oligomerization domain (NOD) proteins 1&2. GLP-1 gene (RT-PCR) modulation and its release (EIA) by C. odorata were confirmed in vivo. From the docking result above, TGR5 was identified as a major target for two key C. odorata flavonoids (5,7-dihydroxy-6-4-dimethoxyflavanone and homoesperetin-7-rutinoside); sodium taurocholate and C. odorata powder included into the diet of the animals both raised the intestinal GLP-1 expression versus control (p < 0.05); When treated with flavonoid-rich extract of C. odorata (CoF) or malvidin, circulating GLP-1 increased by 130.7% in malvidin-treated subjects (0 vs. 45 min). CoF treatment also resulted in 128.5 and 275% increase for 10 and 30 mg/kg b.w., respectively | ||
520 | |a CONCLUSIONS: The results of this study support that C. odorata flavonoids may modulate the expression of GLP-1 and its release via TGR5. This finding may underscore its anti-diabetic potency | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a C. odorata | |
650 | 4 | |a Flavonoids | |
650 | 4 | |a GLP-1 | |
650 | 4 | |a TGR5 | |
700 | 1 | |a Nash, Oyekanmi |e verfasserin |4 aut | |
700 | 1 | |a Inyang, Olumide Kayode |e verfasserin |4 aut | |
700 | 1 | |a Ogidigo, Joyce |e verfasserin |4 aut | |
700 | 1 | |a Enejoh, Ojochenemi |e verfasserin |4 aut | |
700 | 1 | |a Okpalefe, Okiemute |e verfasserin |4 aut | |
700 | 1 | |a Hamada, Tsuyoshi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t 3 Biotech |d 2011 |g 8(2018), 2 vom: 01. Feb., Seite 124 |w (DE-627)NLM217529119 |x 2190-572X |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2018 |g number:2 |g day:01 |g month:02 |g pages:124 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13205-018-1138-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 8 |j 2018 |e 2 |b 01 |c 02 |h 124 |